MX2022005250A - Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. - Google Patents

Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.

Info

Publication number
MX2022005250A
MX2022005250A MX2022005250A MX2022005250A MX2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A
Authority
MX
Mexico
Prior art keywords
capivasertib
acalabrutinib
treat
therapeutic combinations
cell malignancies
Prior art date
Application number
MX2022005250A
Other languages
English (en)
Inventor
Hannah Dry
Brandon Willis
Andrew Bloecher
Jerome Mettetal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022005250A publication Critical patent/MX2022005250A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente divulgación se refiere, en general, a combinaciones terapéuticas de acalabrutinib y capivasertib, y a los correspondientes métodos de tratamiento, composiciones farmacéuticas y kits.
MX2022005250A 2019-11-04 2020-10-30 Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. MX2022005250A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (1)

Publication Number Publication Date
MX2022005250A true MX2022005250A (es) 2022-06-08

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005250A MX2022005250A (es) 2019-11-04 2020-10-30 Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.

Country Status (9)

Country Link
US (1) US20220401442A1 (es)
EP (1) EP4054582A1 (es)
JP (1) JP2023501317A (es)
KR (1) KR20220098175A (es)
CN (1) CN114728003A (es)
AU (1) AU2020381240C1 (es)
CA (1) CA3158321A1 (es)
MX (1) MX2022005250A (es)
WO (1) WO2021089419A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2013010868A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
EP3394044A1 (en) * 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合

Also Published As

Publication number Publication date
AU2020381240C1 (en) 2024-02-15
US20220401442A1 (en) 2022-12-22
CN114728003A (zh) 2022-07-08
AU2020381240B2 (en) 2023-09-07
KR20220098175A (ko) 2022-07-11
JP2023501317A (ja) 2023-01-18
CA3158321A1 (en) 2021-05-14
EP4054582A1 (en) 2022-09-14
WO2021089419A1 (en) 2021-05-14
AU2020381240A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2018009173A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2020001727A (es) Terapia de combinacion.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2019013862A (es) Terapia de combinacion.
MX2017009450A (es) Composicion yodofora novedosa y metodos de uso.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.